Ozempic changed obesity treatment, but experts say the real revolution is next
Medical experts are updating the POWER framework to reflect a more comprehensive approach to obesity treatment beyond just GLP-1 medications like Ozempic. The new model emphasizes a multidisciplinary strategy that integrates surgery, endoscopic procedures, and precision medicine.
Why it matters
As obesity rates rise, shifting the medical consensus toward a holistic, multi-modal treatment model could significantly improve long-term patient outcomes.
The popularity of GLP-1 medications such as semaglutide (Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro and Zepbound) has dramatically reshaped the way obesity is treated. However, specialists say these drugs are only one piece of the puzzle when it comes to managing one of the most widespread chronic health conditions in the United States.
The content is a summary of medical research and clinical guidelines, maintaining a neutral, scientific tone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in